Kalbe Farma builds on healthcare portfolio, shares tracked against regional pharma peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 23:00.

Kalbe Farma (ID1000096605) continues to position PT Kalbe Farma Tbk as a diversified healthcare group in Indonesia. The Jakarta-listed company operates across prescription pharmaceuticals, consumer health and nutrition, which investors often benchmark against regional peers such as Takeda in Japan and Sun Pharma in India.

Business mix across four segments

PT Kalbe Farma Tbk organizes its operations into four main segments: prescription pharmaceuticals, consumer health, nutritionals and distribution/logistics, according to its English-language corporate profile on the official company website. The prescription business covers branded generics, specialty drugs and licensed products sold in Indonesia and selected export markets across Southeast Asia and Africa.

The consumer health division includes over-the-counter medicines, vitamins and herbal products tailored to the Indonesian market, while the nutritional segment focuses on adult and pediatric nutrition, including clinical nutrition for hospitals, as laid out in Kalbe's latest investor presentations on its investor-relations pages on the kalbe.co.id domain. The distribution and logistics arm ensures cold-chain and nationwide product availability, which is critical in a geographically dispersed country such as Indonesia with more than 17,000 islands.

Earnings cycle and analyst coverage

PT Kalbe Farma Tbk typically reports its quarterly and full-year results in line with Indonesian Financial Services Authority requirements, with financial statements published on the Indonesia Stock Exchange (IDX) and on the company investor-relations site. Analysts at regional brokerages and international houses use these reports to update their earnings and valuation models for the stock.

Consensus estimates for Kalbe Farma, as collated by regional equity research platforms that track IDX-listed healthcare names, generally focus on revenue growth in prescription drugs, margin trends in the high-volume consumer health segment and capital expenditure for manufacturing and distribution capacity. Analysts also compare Kalbe's returns and growth profile with Southeast Asian peers in the healthcare and pharmaceutical sector, including companies in Thailand and Malaysia, when framing relative valuation multiples such as price-to-earnings and enterprise value to EBITDA.

Representative product line in consumer health

One well-known product family under PT Kalbe Farma Tbk's consumer health portfolio is the Extra Joss energy drink range, which targets the mass market in Indonesia and selected export countries. The brand, frequently highlighted in marketing materials and promotional campaigns, complements Kalbe's vitamins and over-the-counter medicines by addressing consumer demand for energy and stamina products.

Where the stock trades today

Kalbe Farma shares trade on the Indonesia Stock Exchange in Jakarta under the ticker KLBF, quoted in Indonesian rupiah. At the time of writing, the most recent verifiable market data show the shares changing hands on the IDX; detailed intraday prices and volumes are available on exchange and financial-data platforms that track Indonesian equities.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.